

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

REDESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of OrbusNeich Medical Group Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) announces that Mr. Ching Chung John CHOW (周靜忠) (“**Mr. Chow**”), an Executive Director, has retired from the Group of all executive roles and has been redesignated as a Non-executive Director with effect from September 7, 2023.

Mr. Chow, aged 65, has been a Director since July 22, 2021 and was redesignated as an Executive Director on September 29, 2021. Mr. Chow was the head of business development of the Group, primarily responsible for overseeing overall business development activities of the Group prior to his retirement. Mr. Chow has around 38 years of experience in interventional cardiology. He worked in Cordis-Neich Limited in May 1984 and was promoted as the general manager in January 1991. Prior to joining the Group, he was appointed as the Asia Pacific regional marketing director of the Cordis franchise in Johnson & Johnson in June 1999. After his employment at Johnson & Johnson, Mr. Chow joined the Group in August 2000 and served as the head of sales and marketing for the Asia Pacific region from 2010 to 2015. Mr. Chow was appointed as the director of business development of the Group on May 17, 2006 and was appointed as the head of business development on September 29, 2021. Mr. Chow obtained his Bachelor of Arts degree from York University in Canada in June 1980.

Mr. Chow has entered into a letter of appointment with the Company as a Non-executive Director for a fixed term of three years commencing from September 7, 2023 and is subject to termination in accordance with the respective terms. The term of the letter of appointment may be renewed in accordance with the Articles of Association of the Company and the applicable the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). After redesignation as a Non-executive Director, Mr. Chow is entitled to receive a director’s fee of HK\$240,000 per annum as determined by the Board on recommendation of the remuneration committee of the Board with reference to the prevailing market condition and his duties and responsibilities with the Company.

As at the date of this announcement, Mr. Chow is interested in 307,143 shares of the Company (the “**Shares**”) and 200,000 underlying Shares by virtue of a Pre-IPO Share Option Scheme of the Company.

Save as disclosed above, as at the date of this announcement, in relation to the above redesignation, unless otherwise disclosed above: (1) Mr. Chow does not have any relationship with other Directors, senior management or substantial shareholder or controlling shareholder of the Company; (2) Mr. Chow is not interested in the Shares and underlying Shares within the meanings of Part XV of the SFO; (3) Mr. Chow did not hold any other directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas, or hold other major appointments and professional qualifications; (4) there is no information to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules; and (5) there is no other matter which needs to be brought to the attention of the shareholders of the Company pursuant to Rule 13.51(2) of the Listing Rules.

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN

Chairman, Executive Director and Chief Executive Officer

Hong Kong, September 7, 2023

As at the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ching Chung John CHOW, Mr. Ting San Peter Lionel LEUNG and Dr. Yi ZHOU as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.